This article was originally published in The Gray Sheet
Michael Beatrice named VP-corporate and regulatory science, effective Nov. 1. Beatrice, who has 25 years of regulatory affairs experience having previously held positions in FDA's drugs and biologics centers, could prove valuable in upcoming discussions with the agency about recent compliance problems in the firm's diagnostics division (1"The Gray Sheet" Oct. 4, p. 16). Meanwhile, Abbott acquisition target Perclose has postponed to Nov. 19 its shareholders meeting to consider the combination, citing the uncertainty of the outcome of Abbott's discussions with FDA
You may also be interested in...
Discussions between Abbott Labs and FDA over a proposed consent decree that could halt production of certain diagnostic products likely relate to quality system regulations (QSR) violations detected over a year ago at the firm's Abbott Park, Illinois facility.
The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.